Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201838 · ClinicalTrials.gov registry record · Phase 1
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
A Phase 1 study of Pancreatic Neoplasms and Adenocarcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT00201838 is a Phase 1 study of Pancreatic Neoplasms and Adenocarcinoma that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 38 participants, below the 600-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00201838, a Phase 1 study of Pancreatic Neoplasms and Adenocarcinoma, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this protocol are: 1. To study the safety and tolerability of the combination of etanercept and gemcitabine in patients with advanced pancreatic cancer: 2. To estimate the anti-tumor effect as measured by the proportion of patients free of disease-progression at six months after treatment initiation.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Etanercept
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2001-07 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201838
The ClinicalTrials.gov registry entry for NCT00201838 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (94% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00201838 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00201838 about?
NCT00201838 is a clinical study titled "Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma". The aims of this protocol are: 1. To study the safety and tolerability of the combination of etanercept and gemcitabine in patients with advanced pancreatic cancer: 2. To estimate the anti-tumor effect as measured by the proportion of patients free of disease-progression at six months after treatme...
What is the current status of trial NCT00201838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2001-07. Estimated completion is 2007-05.
What conditions does trial NCT00201838 study?
This clinical trial studies the following conditions: Pancreatic Neoplasms, Adenocarcinoma.
What interventions are being tested in trial NCT00201838?
The interventions under investigation include: Gemcitabine (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT00201838?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00201838 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
-
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.